Skip to main content
Labs/CA-125 Blood Test (Ovarian Cancer)
Clinical Test & Procedure Reference

CA-125 Blood Test (Ovarian Cancer)

This test measures the amount of a protein called CA-125 (cancer antigen 125) in a sample of your blood.

This test measures the amount of a protein called CA-125 (cancer antigen 125) in a sample of your blood. CA-125 is a type of tumor marker. Tumor markers are substances that are often made by cancer cells or by normal cells in response to cancer. Organs in the female reproductive system (such as the ovaries and fallopian tubes) may make CA-125 when those organs are inflamed. This may happen in response to normal bodily functions, such as a menstrual period . However, your body may also produce high levels of CA-125 in response to ovarian cancer . The ovaries are a pair of female reproductive glands that store ova (eggs) and make female hormones . Ovarian cancer happens when the cells in an ovary begin to grow out of control. Other names: cancer antigen 125, glycoprotein antigen, ovarian cancer antigen, CA-125 tumor marker

Why is this test ordered? If you've been diagnosed with ovarian cancer , you may have several CA-125 blood tests: During your treatment to see if your cancer is going away. After your treatment, to check if your cancer has returned. If you have a lump in your pelvis that could be ovarian cancer , your provider may use a CA-125 test to help find out if it could be ovarian cancer. But only a biopsy can diagnose ovarian cancer. If you have a very high risk of getting ovarian cancer , your provider may suggest checking your CA-125 levels. If they're high, you'll probably need more tests to find out if you have cancer. You're more likely to get ovarian cancer if you: Have a mother or sister, or two or more other relatives who've had ovarian cancer. Have family members who've had breast cancer or colorectal cancer (colon cancer). Have inherited certain gene changes or conditions that increase your risk of ovarian cancer, such as: Changes in your BRCA 1 or BRCA 2 genes. Lynch syndrome (also called hereditary non-polyposis colorectal cancer), an inherited disorder that increases the risk for many types of cancer. Have had breast, uterine (uterus), or colorectal cancer. If you're concerned about getting ovarian cancer, talk with your provider about your risk.

Clinical Interpretation

Your provider will review your CA-125 test results along with other information about your condition. Together, you can discuss how your results affect your diagnosis, treatment, and need for more testing. In general: If you are being treated for ovarian cancer , and the results of several tests show that your CA-125 levels are going down, it usually means that the treatment is helping. If your levels go up or stay the same over time, it may mean that the treatment isn't working. If you have finished your treatment for ovarian cancer and your CA-125 levels begin to increase over time, your cancer may be coming back. If you have a high risk for ovarian cancer or have a suspicious pelvic lump , high CA-125 levels could be a sign of cancer. Your provider will usually order more tests to make a diagnosis. While high CA-125 levels don't always mean ovarian cancer, a normal CA-125 test result doesn't rule it out. That's because CA-125 levels may be low in the early stages of cancer. And not everyone with ovarian cancer makes high levels of CA-125. Talk with your provider if you have questions about your results. Learn more about laboratory tests, reference ranges, and understanding results .

Related ICD-10 Codes

C45.1Mesothelioma of peritoneumMedicare medical-necessity (NCD 190.28)C48.1Malignant neoplasm of specified parts of peritoneumMedicare medical-necessity (NCD 190.28)C48.2Malignant neoplasm of peritoneum, unspecifiedMedicare medical-necessity (NCD 190.28)C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneumMedicare medical-necessity (NCD 190.28)C51.8Malignant neoplasm of overlapping sites of vulvaMedicare medical-necessity (NCD 190.28)C53.0Malignant neoplasm of endocervixMedicare medical-necessity (NCD 190.28)C53.1Malignant neoplasm of exocervixMedicare medical-necessity (NCD 190.28)C53.8Malignant neoplasm of overlapping sites of cervix uteriMedicare medical-necessity (NCD 190.28)C53.9Malignant neoplasm of cervix uteri, unspecifiedMedicare medical-necessity (NCD 190.28)C54.1Malignant neoplasm of endometriumMedicare medical-necessity (NCD 190.28)C54.2Malignant neoplasm of myometriumMedicare medical-necessity (NCD 190.28)C54.3Malignant neoplasm of fundus uteriMedicare medical-necessity (NCD 190.28)C54.9Malignant neoplasm of corpus uteri, unspecifiedMedicare medical-necessity (NCD 190.28)C56.1Malignant neoplasm of right ovaryMedicare medical-necessity (NCD 190.28)C56.2Malignant neoplasm of left ovaryMedicare medical-necessity (NCD 190.28)C56.3Malignant neoplasm of bilateral ovariesMedicare medical-necessity (NCD 190.28)C56.9Malignant neoplasm of unspecified ovaryMedicare medical-necessity (NCD 190.28)C57.00Malignant neoplasm of unspecified fallopian tubeMedicare medical-necessity (NCD 190.28)C57.01Malignant neoplasm of right fallopian tubeMedicare medical-necessity (NCD 190.28)C57.02Malignant neoplasm of left fallopian tubeMedicare medical-necessity (NCD 190.28)C57.4Malignant neoplasm of uterine adnexa, unspecifiedMedicare medical-necessity (NCD 190.28)C57.7Malignant neoplasm of other specified female genital organsMedicare medical-necessity (NCD 190.28)C57.8Malignant neoplasm of overlapping sites of female genital organsMedicare medical-necessity (NCD 190.28)C79.60Secondary malignant neoplasm of unspecified ovaryMedicare medical-necessity (NCD 190.28)C79.61Secondary malignant neoplasm of right ovaryMedicare medical-necessity (NCD 190.28)C79.62Secondary malignant neoplasm of left ovaryMedicare medical-necessity (NCD 190.28)C79.63Secondary malignant neoplasm of bilateral ovariesMedicare medical-necessity (NCD 190.28)C79.82Secondary malignant neoplasm of genital organsMedicare medical-necessity (NCD 190.28)D39.0Neoplasm of uncertain behavior of uterusMedicare medical-necessity (NCD 190.28)D39.10Neoplasm of uncertain behavior of unspecified ovaryMedicare medical-necessity (NCD 190.28)D39.11Neoplasm of uncertain behavior of right ovaryMedicare medical-necessity (NCD 190.28)D39.12Neoplasm of uncertain behavior of left ovaryMedicare medical-necessity (NCD 190.28)D39.2Neoplasm of uncertain behavior of placentaMedicare medical-necessity (NCD 190.28)D39.8Neoplasm of uncertain behavior of other specified female genital organsMedicare medical-necessity (NCD 190.28)D39.9Neoplasm of uncertain behavior of female genital organ, unspecifiedMedicare medical-necessity (NCD 190.28)G89.3Neoplasm related pain (acute) (chronic)Medicare medical-necessity (NCD 190.28)M33.03Juvenile dermatomyositis without myopathyMedicare medical-necessity (NCD 190.28)M33.13Other dermatomyositis without myopathyMedicare medical-necessity (NCD 190.28)M33.93Dermatopolymyositis, unspecified without myopathyMedicare medical-necessity (NCD 190.28)R19.01Right upper quadrant abdominal swelling, mass and lumpMedicare medical-necessity (NCD 190.28)R19.02Left upper quadrant abdominal swelling, mass and lumpMedicare medical-necessity (NCD 190.28)R19.03Right lower quadrant abdominal swelling, mass and lumpMedicare medical-necessity (NCD 190.28)R19.04Left lower quadrant abdominal swelling, mass and lumpMedicare medical-necessity (NCD 190.28)R19.09Other intra-abdominal and pelvic swelling, mass and lumpMedicare medical-necessity (NCD 190.28)R97.1Elevated cancer antigen 125 [CA 125]Medicare medical-necessity (NCD 190.28)R97.8Other abnormal tumor markersMedicare medical-necessity (NCD 190.28)Z84.AFamily history of exposure to diethylstilbestrolMedicare medical-necessity (NCD 190.28)Z85.41Personal history of malignant neoplasm of cervix uteriMedicare medical-necessity (NCD 190.28)Z85.42Personal history of malignant neoplasm of other parts of uterusMedicare medical-necessity (NCD 190.28)Z85.43Personal history of malignant neoplasm of ovaryMedicare medical-necessity (NCD 190.28)Z85.44Personal history of malignant neoplasm of other female genital organsMedicare medical-necessity (NCD 190.28)Z85.4APersonal history of malignant neoplasm of fallopian tube(s)Medicare medical-necessity (NCD 190.28)Z91.BPersonal risk factor of exposure to diethylstilbestrolMedicare medical-necessity (NCD 190.28)

Clinical Protocol & Patient Advice

  • 1

    You don't need any special preparations for a CA-125 blood test.

Usage Guidance

  • Reference ranges vary by laboratory. Always discuss your specific results with a qualified healthcare professional.

Source: MedlinePlus, National Library of Medicine. View the original.